Melissa R Junttila

List of Publications by Year
in descending order

20	2,137	471509 17	713466 21
papers	citations	h-index	g-index

22	22	22	4801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	46.4	41
2	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Reports, 2022, 38, 110351.	6.4	18
3	Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1162-1173.	7.0	13
4	RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death and Differentiation, 2020, 27, 161-175.	11.2	100
5	Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discovery, 2020, 10, 232-253.	9.4	466
6	A Stromal Niche Defined by Expression of the Transcription Factor WT1 Mediates Programming and Homeostasis of Cavity-Resident Macrophages. Immunity, 2019, 51, 119-130.e5.	14.3	105
7	Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation. Cell Death and Differentiation, 2019, 26, 2416-2429.	11.2	25
8	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. Npj Precision Oncology, 2018, 2, 7.	5.4	107
9	Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment. Clinical Cancer Research, 2018, 24, 4455-4467.	7.0	88
10	Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells. Nature Communications, 2018, 9, 2992.	12.8	23
11	Transcription factor Etv5 is essential for the maintenance of alveolar type II cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3903-3908.	7.1	94
12	Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10947-E10955.	7.1	58
13	Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS ONE, 2017, 12, e0185862.	2.5	67
14	Castration-Resistant Lgr5+ Cells Are Long-Lived Stem Cells Required for Prostatic Regeneration. Stem Cell Reports, 2015, 4, 768-779.	4.8	36
15	Translational value of mouse models in oncology drug development. Nature Medicine, 2015, 21, 431-439.	30.7	242
16	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 4284-4292.	1.6	431
17	Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. Translational Oncology, 2015, 8, 126-135.	3.7	14
18	Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 40-47.	4.1	48

#	Article	IF	Citations
19	Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Nature Communications, 2014, 5, 3530.	12.8	57
20	Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSFâ€“induced neutrophil recruitment. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6079-6084.	7.1	101